Adrianzén C, Dossenbach M, Leadbetter M

Language: Spanish
References: 52
Page: 86-94
PDF size: 121.40 Kb.

ABSTRACT

Objective: to evaluate the health results and the costs related to the available antipsychotics, with emphasis on olanzapine, in naturalistic outpatient settings. Methods: 572 patients with schizophrenia (ICD-10 or DSM-IV) who began or changed to an oral, antipsychotic were enrolled in blocks of ten: 5 patients for olanzapine and 5 for another antipsychotic, according to the prescription at that time. The effectiveness was measured by the mean change in score on the Global Clinical Impression of Severity of illness Scale (GCI-S). “Clinical response” was defined as the decrease ≥” 2 points on the GCI-S if the baseline score was ≥” 4 and the decrease ≥” 1 if the baseline was ≤” 3. “Minimally symptomatic” was defined as reaching a score of 1 or 2 on the GCI-S after the baseline. Adverse events resulting from the treatment were recorded, along with the use of any concomitant medication and the causes of discontinuation of the medication. Results: The SOHO Andean Region enrolled 272, 97 and 65 patients in monotherapy with olanzapine, typical antipsychotics (TA) and risperidone respectively. Both olanzapine and risperidone were more effective than the TA in improving the general, positive and negative symptoms at 12, 24, and 36 months, but only olanzapine showed a statistically significant difference vs TA in depressive and cognitive symptoms. Less patients on olanzapine developed extrapyramidal symptoms (EPS) and adverse sexual events. The patients on olanzapine demonstrated the lowest rate of tardive dyskinesia at 3 years. More patients on olanzapine gained weight with a statistically significant difference vs risperidone and TA. The mean weight gain with olanzapine was 5 kg and the greatest increase was recorded in the first 12 months of treatment. Conclusions: olanzapine, but not risperidone, was more effective than typicals improving depressive and cognitive symptoms with statistical difference. Olanzapine was better tolerated in terms of EPS, tardive dyskinesia and sexual function impairment. A greater weight gain was recorded with olanzapine; however, the discontinuation rate due to intolerability was the lowest. These results support the greater benefits of Atypicals in terms of effectiveness and tolerability.

REFERENCES

1. Pull Ch. Diagnosis of schizophrenia: A review. In Schizophrenia/Second edition. Edited by Mario Maj & Norman Sartorius. WPA Series Evidence and experience in psychiatry John Wiley & Sons USA 2002.

2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. Fourth edition-Text Revision (DSMIV- TR) American Psychiatric Association, 2000; Washington DC.)

3. Andreasen NC. Symptoms, signs and diagnosis of schizophrenia. Lancet 1995; 346: 477-81.

4. Murray CJ, Lopez AD. The global burden of disease in 1990 and projected to 2020. Cambridge, Harvard University 1996.

5. Lieberman J. Is schizophrenia a neurodegenerative disorder? A clinical and neurobiological perspective. Biol Psychiatry 1999; 46: 729-39.

6. McGlashan TH. Early detection and intervention in schizophrenia: research. Schizophr Bull 1996;22:327-45.

7. Blanchard JB, Nueser KT, Bellack AS. Anhedonia, positive and negative affect, and social functioning in schizophrenia. Schizophr Bull 1998; 24:413-24.

8. Andreasen NC. Affective flattening and the criteria for schizophrenia. Am J Psychiatry 1979; 136: 944-7.

9. Binder J, Albus M, Hubmann W. Neuropsychological impairment and psychopathology in first-episode schizophrenic patients related to the early course of illness. Eur Arch Psychiatry Clin Neurosci 1997;248:70-7.

10. Lieberman J, Perkins D, Belger A. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biological Psychiatry 2001;50: 884-97.

11. Fleischhacker W. Pharmacological treatment of schizophrenia: A review. In: schizophrenia/Second edition. Edited by Mario Maj & Norman Sartorius. WPA Series Evidence and experience in psychiatry John Wiley & Sons USA. 2002.

12. Bressan RA, Costa DC, Jones HM. Typical Antipsychotic Drugs -D(2) Receptor occupancy and depressive symptoms in schizophrenia. Schizophr Res 2002;56 (1-2):31-6.

13. Ichikawa J, Meltzer HY. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psych Clin Neurosci Vol. 249, 1999.

14. Marder SR. Antipsychotic drugs and relapse prevention. Schizophrenia Res 1999;35:S87-S92.

15. Glazer WM. Extra pyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Clin.Psychiatry 2000;61 Suppl 3:16-21.

16. Arana GW. An overview of side effects caused by typical antipsychotics. J Clin Psych 2000;61 Suppl 8:5-11.

17. Beasley CM, Tollefson GD, Satterlee W. Olanzapine vs placebo: results of a double blind, fixed dose olanzapine trial. Psychopharmacology 1996; 124: 159-67.

18. Beasley CM, Tollefson GD, Tran P. Olanzapine vs placebo and haloperidol: acute phase results of the North American doubleblind olanzapina trail Neuropsyhcopharmacol 1996;14:111-23.

19. Beasley CM Jr, Hamilton SH, Crawford AM. Olanzapine vs haloperidol: acute phase results of the international doubleblind olanzapine trial. Europ Neuropsychopharmacol 1997;7:125-37.

20. Tollefson GD, Beasley CM Jr, Tran PV, Street J, Krueger J, Tamura RN, et al. Olanzapine vs haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psych 1997;154:457-65.

21. Tran PV, Hamilton SH, Kuntz AJ. Double-blind comparison of olanzapine vs risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:407-18.

22. Kinon B, Noordsy DL, Liu-Seifert H. Randomized, double-blind 6-month comparison of olanzapina and quetiapina in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol 2006;26:453-61.

23. Breier A, Berg P, Thakore J. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia. Am J Psychiatry 2005;162:1879-87.

24. Lehman AF, Kreyenbuhl J, Buchanan RW. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations. Schizophr Bull 2004;30(2):193-217.

25. Miller AL, Hall CS, Buchanan RW. The Texas medication algorithm project antipsychotic algorithm for schizophrenia: 2003 update. Clin Psychiatry 2004;65(4):500-8.

26. Davies J, Chen N, Glick I. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-64.

27. Volavka J, Czobor P, Sheitman B. Clozapine, olanzapine, risperidone and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder. Am J Psychiatry 2002; 159: 255-62.

28. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998;317(7167):1181-4.

29. Stahl S. “Does evidence from clinical trials in psychopharmacol apply in clinical practice?” J Clin Psychiatry 2001; 62: 6-7.

30. McKee M, Britton A, Black N. Methods in health services research. Interpreting the evidence: choosing between randomized and non-randomized studies. BMJ 1999;319 (7205):312-5.

31. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. New England J Med 2000;342(25):1887-92.

32. Benson K, Hartz AJ. A Comparison of observational studies and randomized, controlled trials. New Eng J Med 2000; 342(25):1878-86.

33. Gorwood P. “Meeting everyday challenges: antipsychotic therapy in the real world” Europ Neuropsychopharmacol 2006; 16: S156-S162.

34. Kasper S, Rosillon D, Duchesne I. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): efficacy and tolerability results of an international naturalistic study. Int Clin Psychopharmacol 2001;16(4):179-87.

35. Chouinard G, Kopala L, Labelle A. Phase-IV multicentre clinical study of risperidone in the treatment of outpatients with schizophrenia. The RIS-CAN-3 study group. Can J Psych 1998;43(10):1018-25.

36. Haley JC, Russo PA, Buesching DP. “Schizophrenia care and assessment program, SCAP: a naturalistic approach to measuring schizophrenia outcomes”. Europ Neurospychopharmacology 1998; 8 (Suppl 2) :S217.

37. Ciudad A, Gutierrez M, Cañas F. Safety and effectiveness of olanzapine in monotherapy: a multivariate analysis of a naturalistic study. Progress Neuro-Psychopharm Biol Psych 2005;29: 944-51.

38. Gómez JC, Sacristán JA, Hernández J. The safety of olanzapina compared with other antipsychotic drugs: results of an observational prospective study in patients with schizophrenia (EFESO study) J Clin Psych 2000; 61: 335-43.

39. Dossenbach M, Erol A. Mahfoud K. Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risepridone, and haloperidol. J Clin Psych 2004; 65 (3): 312-21.

40. Ascher-Svanum H, Zhu B, Faries D, Landbloom R, Swartz M, Swanson J. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia. BMC Psychiatry 2006;6:8.

41. Lieberman JA, Stroup S, McEvoy J, Swartz M, Rosenheck R, Perkins D. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: primary efficacy and safety outcomes of the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial. N Engl J Med 2005; 353:1209–23.

42. Dossenbach M, Arango-Dávila C, Silva H. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-months follow-up of the Intercontinental Schizophrenia outpatient health outcomes (IC-SOHO) Study. J Clin Psychiatry 2005; 66 (8):1021-30.

43. Purdon SE, Jones BDW, Stip E. Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch General Psych 2000;57:249-58.

44. Bilder R, Goldman R, Volavka J. Neurocognitive effectos of clozapine, olanzapine, risperidone and haloperidol in patients with chronic schizphrenia or schizoaffective disorder. Am J Psych 2002;1018-28.

45. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational, multicentre, double-blind, parallelgroup study versus haloperidol. Risperidone study group. Br J Psychiatry 1995;166(6):712-26.

46. Huang ML, Van Peer A, Woestenborghs R. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Clin Pharmacol Ther 1993;54(3):257-68.

47. Maguire G A. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psych 2002;63 Suppl 4:56-62.

48. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clinical Psych 1997;58[SUPPL.10], 45-9.

49. Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC. Antipsychotic-induced weight gain: a comprehensive research synthesis. Ame J Psych 1999;156[11]: 1686-96.

50. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psych 1999;60[6], 358-63.

51. Evans S, Newton R, Higgins S. Nutritional intervention to prevent weight gain in patients commenced on olanzapina: a randomized controlled trial. Australian and New Zealand J Psych 2005;39:479-86.

52. Kwon JS, Choi JS, Bahk WM. Weight management program for treatment-emergent weight gain in olanzapine-treated patients with schizophrenia or schizoaffective disorder: a 12- week randomized controlled clinical trial. J Clin Psychi 2006; 67(4):547-53.